US drugmaker AbbVie (NYSE: ABBV) has expanded its eye care portfolio in a deal with Belgian company iSTAR Medical.
The strategic transaction is for the further development and commercialization of iSTAR Medical's MINIject device, a minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma.
MINIject received Conformité Européenne marking approval to commercialize in European countries in the last quarter of 2021 and launched commercially in select European countries in early 2022.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze